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The purpose of this study is to evaluate the usefulness of the new real-time PCR COBAS TaqMan 48
analyzer, comparing it to the existing COBAS AMPLICOR HBV MONITOR based on conventional PCR
technology. The study used 104 samples from different patients. No differences were found in the sensitivity of
the tests. There was an excellent correlation between the sample with a viral load within the dynamic range of
the two tests (r  0.938). The COBAS TaqMan test has a wider linear range, and this fact enables quantifying
of the viral load without diluting the sample.
Hepatitis B virus (HBV) is a member of the family Hepad-
naviridae that causes acute and chronic hepatitis (6). It is es-
timated that 2 billion people have been infected by HBV all
over the world and more than 350 million people have persis-
tent infection (11). The availability of molecular diagnostic test
has improved the handling of the disease and monitoring of the
response to treatment (12). The main purpose of measuring
HBV DNA is to confirm the activity of infection and possible
candidacy of patients for antiviral treatment.
One of the present tests for amplification of target is the
AMPLICOR HBV MONITOR test (Roche Molecular Sys-
tems) which is based on the amplification of DNA targets by
the use of HBV-specific primers. The quantitative PCR system
used in the MONITOR test calculates the initial amount of
DNA by measuring it at the end of the amplification reaction
(2). The results thus obtained are subject to errors caused by a
“plateau” effect that occurs because of accumulation of the
substance, exhaustion of the enzyme, dilution of reagents, and
other reasons. This effect produces a reduction in the rate of
exponential accumulation of final product (5).
The quantitation of real-time PCR is based on the evalua-
tion of the threshold cycle (Ct) when the amplification products
are detected for the first time. The amplified product is de-
tected sooner when the initial viral load is higher. real-time
PCR has a greater precision in quantitation because the Ct
value is observed when the PCR is still in the exponential
phase and so provides a more reliable measurement than when
the amplified product is measured “at the endpoint” as in
conventional PCR (8).
The aim of this study was to evaluate the validity of the
COBAS TaqMan 48 real-time PCR analyser (Roche) for de-
tection and quantitation of HBV DNA in plasma, comparing
the results to those obtained with the same samples using
COBAS AMPLICOR MONITOR (Roche) PCR analyzer.
The study was carried out using 104 blood samples collected
from individual patients. The extracted blood was introduced
in BD VACUTAINER tubes with 1 ml of ACD anticoagulant.
The plasma obtained was divided in two parts. The quantita-
tion of HBV DNA was carried out in parallel by AMPLICOR
and TaqMan analyzers.
The HBV DNA for COBAS TaqMan was isolated by a
manual and generic preparation sample kit (High Pure System
viral nucleic acid kit), based on the bonding of nucleic acid to
glass fibers, in accordance with the manufacturer’s instructions.
TaqMan technology uses the 5-3 nuclease activity of thermo-
stable Z05 DNA polymerase. It uses double-marked fluores-
cent hybridization probes that bond specifically to the sample
between primers. The probe contains a fluorescent marker
(reporter) and another colorant that inhibits the reporter flu-
orescence (quencher). The degradation of the hybridization
probe releases the reporter, causing an increase of fluores-
cence emission. The COBAS TaqMan test quantifies the am-
plicons during the exponential phase of amplification. The
appearance of specific fluorescent signal is considered a critical
threshold value (Ct). The Ct is defined as the number of frac-
tional cycles in which the fluorescence emitted by the sample
exceeds a preset threshold (assigned level of fluorescence) and
marks the beginning of an exponential growth phase of this
signal.
Performance of the AMPLICOR test also requires isolating
the HBV DNA using a manual system that involves many lysis
reagents to obtain the extract through successive centrifuga-
tions and incubations at 100°C. The amplification and detec-
tion are performed by the COBAS AMPLICOR HBV MON-
ITOR test, which also uses the highly conserved precore/core
region of HBV as the target. A colorimetric enzymatic reaction
at the end is used for detection.
Besides viral load, both tests were also compared in regard
to the DNA extraction procedure used by each one. The first
variable compared was the time involved in a complete extrac-
tion. The work unit was 24 samples to be processed (controls
are handled in the same way as clinical samples). The AMPLI-
COR extraction kit requires an average of 2 h of work, the
same as for the High Pure System for COBAS TaqMan. The
extraction phase for COBAS TaqMan requires practically ex-
clusive dedication throughout the process. However, extraction
for AMPLICOR enables the technician to have some free time
during the test to perform other routine laboratory functions,
a very important aspect in clinical microbiology laboratories. A
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FIG. 1. Correlation between viral loads detected by the two tests in group A samples (Passing-Bablok and Bland-Altman).
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comparison was also made of the technical difficulty of both
options. The High Pure System proved to be more laborious
and requires equipment that is not normally found in a labo-
ratory.
In amplification and detection, the first variable of interest
was the time taken to process 24 samples. The results in this
regard were favorable for the COBAS TaqMan test. Results
can be obtained using AMPLICOR in 5 hours, whereas the
average time taken with the TaqMan unit was 2.5 hours. An-
other point of interest is the difference between both assays
regarding the sensitivity of the test and its dynamic range.
The correspondence between results was studied by dividing
the 104 samples into the following groups: group A, patients
with viral loads within the range of both tests (56 samples);
group B, patients with viral loads below the detection limit of
both tests (34 samples); group C, patients with viral loads
outside the range of the AMPLICOR test (14 samples); Viral
loads were converted into logarithms for easier handling. Pass-
ing-Bablock and Bland-Altman statistical tests were used to
establish the agreement between both tests (1, 3) (Fig. 1). The
resulting correlation coefficient was r  0.938. In group B
samples the viral load was undetectable with both assays,
therefore there was complete correlation between AMPLI-
COR and TaqMan. In the group C samples an attempt was
made to assess the importance of having a test with a wide
dynamic range such as COBAS TaqMan. With the COBAS
AMPLICOR MONITOR HBV analyzer there were 14 sam-
ples whose viral load was outside the range limits of technique
(200 copies/ml to 200,000 copies/ml), 12 above the upper limit,
and 2 below the lower limit. Using the COBAS TaqMan unit
was possible to quantify the viral load within the limits of its
dynamic range (110,000,000 IU/ml [660,000,000 copies/ml] to
30 IU/ml [180 copies/ml]) in nine samples (64%). (Table 1).
Many techniques have been described for quantifying HBV
DNA by PCR technology (4, 7, 9) and some of them have come
onto the market. This ios the case of the semiautomatic AM-
PLICOR HBV MONITOR and its predecessor (AMPLICOR
HBV MONITOR in microtiter plates). Many studies mention
their great sensitivity (13, 14). The commercial introduction of
real-time PCR technology has meant an advance in the han-
dling of HBV viral load. In the samples used in our study there
was no difference in sensitivity of the tests, as all the samples in
which COBAS AMPLICOR did not detect viral load, neither
was it detected by COBAS TaqMan analyzer.
In the group of patients where the viral load was within the
range of the AMPLICOR test there was excellent correlation
with the results of the TaqMan unit. This coincides with results
published in other studies which show that real-time PCR
technology has a good degree of correlation with conventional
PCR techniques (16, 17).
One inconvenience found with the AMPLICOR test in pre-
vious studies was its narrow dynamic range (14, 10, 15). This
means that in a lot of samples previous dilution is necessary to
extend the test range (10, 15, 16, 17). One of the technical
characteristics of real-time PCR is its greater dynamic range
(16). Our results show that 9 of 14 samples whose viral loads
were outside the range of determination for the AMPLICOR
test could be quantified using the TaqMan assay without di-
luting the sample. In conclusion, it can be said that the COBAS
TaqMan 48 analyser provides faster results than AMPLICOR,
both tests have excellent correlation in samples with viral load
within the dynamic range of both assays (r  0.938) and the
greater dynamic range of COBAS TaqMan test provides more
exact results without diluting the sample, especially in patients
with very high viral loads.
The results obtained in this and other studies do not inval-
idate the use of COBAS AMPLICOR in laboratories that do
not have real-time technology available. The quantitation of
HBV DNA offered by COBAS AMPLICOR is extremely im-
portant in the management of large numbers of patients for
confirming the condition of active replication as well as for
evaluating response to treatment. Its use would therefore be
justified and its validity demonstrated as a first step in fol-
low-up of these patients. However, the characteristics of the
test in real time justify its use in patients whose evaluation or
follow-up cannot be considered certain within a linear range
narrower than the conventional test. The fact that the proce-
dure for the extraction of DNA for the AMPLICOR test is less
laborious could be an element in its favor for use in smaller
laboratories with fewer technical staff. An automatic system for
the extraction of HBV DNA will become available in the near
future, and this will further simplify this process.
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